Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Wave Life Sciences, Inc. WVE

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$42.7M
▼ 60.5% YoY
$-204.4M
$-188.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our pipeline is focused on our obesity (WVE-007), alpha-1 antitrypsin deficiency ("AATD") (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs for Duchenne muscular dystrophy ("DMD") and Huntington's disease ("HD"), as well as several preclinical programs utilizing our versatile RNA medicines platform. We were incorporated under the name Wave Life Sciences Pte. Ltd. (Registration No.: 201218209G) under the laws of Singapore on July 23, 2012. In preparation for our initial public offering, on November 5, 2015, Wave Life Sciences Pte. Ltd. converted from a private limited company to a public limited company known as Wave Life Sciences Ltd. ("Wave"). Wave has four wholly-owned subsidiaries: Wave Life Sciences USA, Inc. ("Wave USA"), a Delaware corporation (formerly Ontorii, Inc.); Wave Life Sciences Japan, Inc. ("Wave Japan"), a company organized under the laws of Japan (formerly Chiralgen., Ltd.); Wave Life Sciences Ireland Limited ("Wave Ireland"), a company organized under the laws of Ireland; and Wave Life Sciences UK Limited ("Wave UK"), a company organized under the laws of the United Kingdom. As of December 31, 2025, we employed 317 employees, all of whom were full-time employees.

Written from the business description in Wave Life Sciences Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 42.7M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 42.7 · Net income -204.4
50M100M-100M-200M
20132016201920222025
Compound annual growth
+127.1%
+16.3%
+75.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−478 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -504.1% · Net -478.3%
-5000%-10000%
201320192025
ROE
FY2025 · ROE -56.2%
-100%-200%
201320192025
Three returns, three denominators.

Each USD of equity lost 56 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -188.2
-100M-200M
201320192025

Total assetsUSD 638.5M
EquityUSD 518.4M
CashUSD 602.1M
Current ratio6.47×

Equity funds 81% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
WVE, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.10.10.00.00.00.00.00.00.00.0◌◌
Operating income $B−0.2−0.1−0.1−0.2−0.1−0.2−0.2−0.2−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.2−0.1−0.1−0.2−0.1−0.1−0.2−0.2−0.1−0.1◌◌◌
Income tax $B0.00.0−0.00.0−0.0−0.00.00.00.00.00.00.0−0.0
Net income $B−0.2−0.1−0.1−0.2−0.1−0.1−0.2−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.2−0.2−0.0−0.1−0.1−0.1−0.2−0.0−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−1.21−0.70−0.54−2.05−2.36−3.82−5.72−5.06−3.85−2.44−1.83−1.34−1.90
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−56.2−77.9——−212.1−204.6−282.5−137.7−74.4−38.6−24.7——
Shares out B0.190.150.120.090.060.050.030.030.030.020.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image